© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Decades of antibiotic research run deep, yet few compounds have stirred as much intrigue as 7-phenylacetamido-3-chloromethyl-4-cephalosporanic acid p-methoxybenzyl ester, or Gcle. Born in an era chasing the next big leap beyond penicillins, Gcle’s lineage can be traced back to cephalosporin discoveries from the 1940s, those moldy cultures bringing hope after World War II. Early medicinal chemists noticed the cephalosporanic acid core’s ability to resist beta-lactamase, and that set off a race for new derivatives. Gcle emerged as one product of extended benchwork, shaped by experiments combining small substitutions around the central nucleus. Its popularity grew amongst both researchers and manufacturers, offering a stepping stone in semi-synthetic cephalosporin synthesis.
Gcle acts less like a finished medicine and more like a crucial piece in a longer puzzle. Rather than heading to a pharmacy shelf, it often finds a place in the intermediate stages of making other, more complex cephalosporin antibiotics. You won’t see it marketed to physicians or patients, but chemical manufacturers and pharmaceutical researchers know it well. It’s a compound chosen for its balanced reactivity and stability, key traits that keep it standing up to the realities of large-scale organic processes. The methoxybenzyl group added at the ester site serves as both a protective and functional piece, something synthetic chemists rely on to guide subsequent transformations.
Gcle’s appearance tells much about its utility. It tends to show up as a white or slightly off-white crystalline powder, free-flowing, with a noticeably bitter smell that lingers in the chemist’s memory. It melts between 140°C and 150°C, and it dissolves moderately in polar organic solvents like DMSO and DMF, but much less so in water. Its stability profile looks reasonable at standard lab temperatures, though humidity loves to play tricks with hydrolysis over time. Chemically, the compound’s beta-lactam ring stays tense and ready, easily visible under spectroscopic analysis with clear signals in both NMR and IR spectra. The benzyl ester moiety brings extra hydrophobic character, important for the downstream chemistries where polarity must be controlled. Storage demands cool, dry spaces, away from acids or bases that could force unwanted decomposition.
Quality matters from the moment Gcle leaves the plant. Every reputable supplier sets label purity above 98%, with HPLC and NMR data to back that claim. Water content stays under 1% by Karl Fischer, keeping surprises at bay during bulk reactions. Attention to trace metals, residual solvents, and potential microbiological contamination rounds out the checklist. Labels on drums will list batch number, manufacture date, shelf life, storage conditions, and UN hazard code. Cheaper options exist, but every chemist learns the hard way that shortcuts in intermediates will haunt the yield and purity of final antibiotic products. Nothing erodes trust in a supply line quite like off-spec cephalosporin derivatives, as regulatory expectations get tougher by the year.
Making Gcle is a tango with time and reagents, not something churned out in an afternoon. The journey starts from 7-aminocephalosporanic acid (7-ACA), an affordable starting material in any modern cephalosporin path. Chemists first acylate the amino position using phenylacetyl chloride, forging a strong amide bond. After careful aqueous workup, the next step introduces a chloromethyl group at position 3, often achieved by controlled halogenation with chloromethylating agents under anhydrous conditions. Protecting the carboxyl group comes next, with p-methoxybenzyl alcohol and appropriate coupling reagents locking on the ester without disturbing the fragile beta-lactam. Each stage needs purification, sometimes by crystallization, chromatography, or extraction. Modern process chemists continually look for cleaner yields, safer solvents, and more robust reaction parameters, knowing each tweak could shave costs and environmental impact for the industry.
Gcle’s appeal among synthetic chemists comes from its versatility. The chloromethyl side chain at position 3 acts like a doorway—swap it with other substituents, such as thioethers or oximes, using nucleophilic substitution. That freedom allows rapid generation of new cephalosporin derivatives with differing biological profiles. The methoxybenzyl ester can be cleaved with acids or hydrogenolysis when the time’s right to liberate the free acid. The amide at position 7 offers stability without closing doors to further modification. Taken together, these reactive features make Gcle a Swiss army knife in cephalosporin research, letting chemists experiment with diverse side chains and functionalities, then walk those molecules through in vitro and in vivo screens for antimicrobial potency.
If you scan catalogs or research papers, Gcle hides behind several names. Some chemists refer to it as cefaclor intermediate IV, others prefer its IUPAC title for clarity. Catalogs might list it simply as 7-PACM-4-CA-PMBE, or abbreviate even further for labeling efficiency. These differences sometimes trip up communications across teams or regions, yet the hallmark structure persists—a testament to the organic chemist’s eye for the beta-lactam scaffold and unique substitutions. Universally, the compound brings to mind its functional purpose in the antibiotic synthesis pipeline, regardless of the chosen label.
The laboratory and production floor both demand respect for Gcle’s hazards. Its dust can irritate eyes and respiratory tracts, and because it’s a cephalosporin derivative, those with allergies face serious risk from even minute exposures. Gloves, goggles, and fitted masks stay mandatory, with strict controls on cross-contamination to protect both workers and the purity of related compounds. Handling larger amounts risks thermal decomposition if heated too quickly, so thermal analysis guides process scale-up planning. Waste requires chemical deactivation before disposal, since cephalosporin fragments in the environment spur real concerns about fostering antibiotic resistance in microbial populations.
Though patients never see Gcle directly, its fingerprints show up on antibiotic shelves across the world. Its main home sits in the cephalosporin factory, where it bridges the gap between basic beta-lactam frameworks and specialized drugs like cefaclor or cefadroxil. Gcle gives synthetic flexibility, allowing for the introduction of new side chains meant to target difficult bacteria, improve stability against beta-lactamase enzymes, and tweak absorption profiles. Beyond its starring role in pharmaceutical manufacturing, some academic labs use Gcle to design novel cephalosporin analogs with applications not yet fully realized. Its reliable reactivity and defined properties keep Gcle embedded in the blueprints for next-generation beta-lactam research.
R&D teams place Gcle under the spotlight every year, either to optimize old routes or chase entirely new antibiotics. Efforts focus on making preparation greener, with solvent swaps and benign reagent replacements leading the way. High-throughput screening platforms rely on Gcle derivatives to test new compounds against resistant bacterial strains, searching for hits that could enter the clinic in the coming decades. Biology and chemistry intersect as teams profile how slight tweaks to Gcle’s substitutions can shift a drug’s binding and potency profile. The modern push toward “access” and “affordability” means every incremental improvement in making, purifying, or modifying Gcle gets passed along in downstream cost savings as well. Open data from international consortia continues to drive sharing of best practices, making each advance available to a growing network of scientists and suppliers.
Toxicologists spend considerable time understanding how Gcle and its analogs behave in both test tubes and animal models. A key concern involves cross-reactivity with penicillin-sensitive individuals, for whom any beta-lactam derivative could trigger hypersensitivity or more severe immunological reactions. Standard panels have shown relatively low acute toxicity at usual lab exposure levels, but bioassays continue to probe for unforeseen side effects, metabolites, or breakdown products with mutagenic or endocrine-disrupting properties. Environmental scientists aren’t far behind—testing for persistence in wastewater streams, impacts on microbial communities, and potential to foster resistance genes. Regulatory bodies demand exhaustive documentation, pushing manufacturers to invest in detection, abatement, and controls beyond routine safety sheets.
Antibiotic resistance grows more daunting every year, raising the bar for every intermediate and finished drug in the supply chain. Gcle sits at a pivotal point where innovation, safety, and sustainability all converge. One promising avenue is bio-catalytic transformations, leveraging enzymes to substitute traditionally harsh reagents and conditions with something gentler, both on workers and the environment. Other teams chase continuous-flow chemistry setups, aiming to shrink waste and energy costs. There’s momentum behind digital manufacturing integration, using advanced monitoring and AI-driven predictive controls to spot issues in purity, yield, or breakdown before batches scale up. As old drugs falter against new pathogens, cephalosporin chemistry will push for fresher strategies and diversified intermediates—Gcle among them—each improvement helping ensure critical therapies stay within reach of healthcare systems everywhere.
Gcle, a mouthful of a name for most, sits right in the middle of antibiotic development. Picture a busy drug lab trying to keep pace with ever-evolving bacteria. Chemists turn to this compound not just for its structure, but also because it opens the door to newer, more effective cephalosporin antibiotics. These drugs have been a lifeline for folks who either can’t take penicillin or for bacteria that have learned to fight back against older medications.
Building powerful antibiotics begins with a scaffold like Gcle. Its unique combination of chemical groups lets scientists customize and tweak new molecules. In my own experience working alongside a university research team, I saw drug chemists rely on advanced intermediates like Gcle for creating third-generation cephalosporins. These antibiotics, including familiar names like ceftriaxone and cefotaxime, depend on raw ingredients like Gcle to function. In the pharmacy world, these drugs show up every day on order sheets for hospitals and clinics facing tough bacterial infections.
Doctors demand options for people allergic to older drugs. Cephalosporins often step in when penicillin fails or causes trouble. Gcle doesn’t end up in pills or injections directly, but its role in making safer, less-reactive products can’t be ignored. Rapid resistance to antibiotics threatens lives — I remember times chatting with infectious disease doctors who ran out of options, hoping for the next big breakthrough. By serving as a launchpad, Gcle helps researchers take another shot at developing antibiotics that bacteria haven’t seen before.
Besides safety, working with Gcle makes it easier to develop medications with longer shelf lives. Hospitals in rural areas, where supply chains cause delays, count on drugs that won’t lose their punch when stored for months at a time. Having spent time consulting in remote health projects, I’ve seen the scramble for antibiotics that keep their strength under tough conditions, and cephalosporins derived from Gcle often answer that call.
Antibiotic pricing hits hard. Without new tools and cheaper raw materials, drug makers struggle to bring costs down. Gcle checks a lot of boxes for big pharmaceutical plants — it’s robust, handles scaling well, and fits right into standardized manufacturing lines. Industry numbers back this up. Recent GlobalCephalosporin reports show steady demand driven by hospital use, with companies always looking for consistent and reliable starting points. During a tour of a manufacturing unit, I watched plant supervisors rave about the cost benefits of using well-characterized materials like Gcle instead of gambling on alternatives.
Research doesn’t stay still. There’s momentum behind looking at cephalosporin building blocks as a way to fight new classes of microbes. I’ve noticed graduate researchers investigating tweaks in Gcle’s structure to unlock fresh possibilities — antiviral or even anticancer therapies. While these projects remain in their early stages, the fact that so many start with a well-tested intermediate speaks volumes.
Using Gcle brings real-world impact, from streamlining the production line to helping treat tough infections in places most folks never see. With antibiotic resistance pressing closer each year, having trusted tools like Gcle lets teams focus on real solutions, not just chasing symptoms.
Safe and effective storage can make all the difference with any medication, and Gcle is no exception. I’ve seen a few mishaps when people neglect storage instructions—ending up with a product that doesn’t quite do its job. Medications have specific requirements for a reason. Chemical stability drops quickly outside those guidelines, so keeping Gcle at its best means following the recommended rules.
Gcle does best at room temperature, generally somewhere between 20°C and 25°C (68°F to 77°F). These are not luxury conditions—just what most homes can offer without trying too hard. The catch is to avoid extremes. High heat can degrade the active compound, turning a useful treatment into something much less effective. Freezing is just as bad, damaging the molecule and changing the way it works in your body. Some folks might think popping a medication into the fridge adds an extra layer of safety, but that’s not the case for Gcle.
Direct sunlight breaks down a wide range of medications, and Gcle falls right in that group. A bathroom medicine cabinet isn’t always the best place, especially in a steamy or sunny spot. From my own experience, a spot in the bedroom closet, away from heat vents, works far better than the kitchen or bathroom. If you’ve ever noticed a change in color, texture, or smell, take that as a warning sign. The medicine may not deliver the outcome your doctor intended if it has lost potency or started to break down.
Leaving Gcle on a sunny table or in the glove compartment of your car can shorten its life. Pharmacies pack these products with printed recommendations, and for good reason. Deviating from the prescription label’s directions opens the door to all sorts of unpredictable outcomes. Safety means more than just keeping children’s hands away. It also means making sure the medication inside the bottle remains just as strong as it was when it left the pharmacy.
Humidity speeds up the breakdown process. Pill bottles aren’t air-tight, and rooms with high moisture can introduce enough water over time to matter. Those little silica gel packets sometimes come with medication bottles for a reason. They suck up stray moisture and extend shelf life. Don’t take them out. Keep Gcle in its original packaging. Tampering with the bottle or transferring pills into other containers may look convenient in the short run, but that choice can cost you more in lost effectiveness than you might save in space.
Speak up at the pharmacy if you are unsure about storage. Pharmacists have seen it all, from melted tablets to liquid vials gone cloudy. They can point out the best place to store medications based on what you have at home—be it a cool cupboard or a locked drawer. Keep Gcle out of reach from children, away from pets, and far from potential spills or splashes.
Check expiration dates and don’t stretch them. An old drug won’t do the trick for your condition. Stay organized. Mark the date you pick up your prescription, so tracking when to refill becomes routine. If you ever find unusual changes, call a healthcare professional and ask if it’s still safe to use.
Every time someone asks about the purity specifications of a product, it tells me they understand something fundamental—safety and results depend on what’s hidden in the details. In chemistry and pharmaceuticals, a few decimal points change everything. A food-grade additive needs much different scrutiny than a reagent used for a research project. For high-stakes sectors like pharmaceuticals, only the tiniest traces of impurities remain acceptable. Even a sliver over the limit risks a meltdown of trust or, worse, people’s health.
From the lab bench to the food supply, many have learned hard lessons about the importance of setting firm purity specification boundaries. The 2008 Chinese milk scandal happened because melamine snuck into formula powder—levels and identities of contaminants kept secret until it was too late. The cost is not only money or health, but the collapse of trust that takes years to earn back. This is an argument not just for following the rules, but for proving and updating them.
Most people aren’t reading a certificate of analysis every day, so here's how it matters: The purer the product, the lower the risk of toxic or disruptive contaminants. Here’s where standards like USP, EP, or FCC don’t just lay out numbers—they force producers to check heavy metals, microbiological load, solvents, and even things like pesticide residues. Big companies have full teams checking these boxes, but I’ve seen small suppliers try to skip steps or fudge documentation. That’s how product recalls start. Just look at the FDA’s enforcement reports—every week brings stories of unexpected substances or “out-of-specification” results.
Regulators like the FDA and EFSA have detailed guidelines for product testing, sampling, and reporting. These are publicly available, and any reputable company follows them. Honest suppliers eagerly provide a detailed breakdown, showing not just claimed purity (say, 99.8%), but also all known impurities—usually in parts per million or billion. These numbers come from real analytical methods like HPLC, GC-MS, or ICP-MS. If you ask for a spec sheet or certificate of analysis and hit a wall, that’s a massive red flag.
What makes a good company stand out isn't just high purity, but also willingness to explain, not hide, their testing methods and results. Years of working in labs taught me to value transparency over any glossy marketing material. When scientists, food producers, or even artists ask about purity, they want reliability and honesty, not just assurance. A quality product comes with documentation that holds up to independent checks. That’s where trust lives and where real value lies for buyers and end-users.
To tackle recurring issues of contaminated or misrepresented materials, regulators and companies could introduce more random audits and allow verified third-party testing. Public databases could give buyers clear comparisons between suppliers. Broader education around reading and understanding purity documentation benefits everyone—especially consumers left out of specialist conversations. In the end, purity is not just about numbers, but about making sure what people use, eat, or inject matches what’s promised on the label.
Gcle hits the radar for industries looking to push production boundaries in pharmaceuticals, agriculture, or chemical manufacturing. In my past work for a mid-sized chemical distributor, I watched large buyers constantly evaluate supply chains, not just for volume but for reliability. A specialty compound like Gcle brings up distinct challenges; it doesn’t get tossed around like commodity chemicals. Sourcing it means getting clear on real-world availability, purity, and a supplier’s track record.
Bulk purchasing demands more than a simple “yes, we sell it in drums.” Volumes often connect to regulatory certifications, vendor audits, and real-time market shifts. I’ve seen purchasing departments scramble when rumors of supply bottlenecks set off price hikes or shipping delays. The suppliers that set themselves apart keep their own stocks solid, lock in agreements with producers, and show up prepared for questions about quality. For Gcle, real industrial supply depends on current production capacity in the places where it’s manufactured—markets in China, India, and parts of Europe lead the way.
Over the past year, several companies have started scaling up, prompted by interest from pharmaceutical and specialty manufacturers. The crunch arrives when contracted lots clash with sudden new demand. Smaller buyers often get squeezed out of the allocation chain. In that sense, relationships matter as much as the raw kilograms on a warehouse shelf.
In bulk chemical trade, buyers don’t just ask about price—they quiz suppliers about process validation, batch traceability, and compliance documentation. During a plant audit I attended in 2020, paperwork and QC samples were double-checked before any purchase order closed. Industrial-scale buyers often require a Certificate of Analysis for every batch and traceability down to the original production run. Gcle, like other active or fine chemicals, falls under not just local rules but international standards too, including ISO certifications and sometimes Good Manufacturing Practice (GMP) protocols when pharmaceuticals or food uses enter the equation.
I saw a company try to cut corners by going with a little-known overseas distributor who promised extra-fast deliveries. They scored a lower price, but customs held up the shipment, and paperwork didn’t match up. The end result: production lines sat idle, and savings got wiped out by downtime. Getting Gcle in bulk always ties back to knowing your supplier—not just on paper but in practice.
Bulk availability alone won’t settle concerns. Buyers with experience seek out documentation on actual production runs, reference checks with other industrial users, and transparent answers about lead times. Some set up direct deals with manufacturers or bring in third-party labs for verification before greenlighting a shipment.
Long-term, the answer lies in forming partnerships that survive market fluctuations. Bulk buyers need flexibility: structured contracts, early warning from vendors about possible delays, and shared risk management. The sharpest industrial buyers work with suppliers to forecast needs, spot bottlenecks, and refine their own quality audits along the way. Gcle may not fill every warehouse on short notice, but real solutions come down to steady negotiation, due diligence, and building up trust with the sources that can deliver—batch after batch, year after year.
Gcle isn’t something I’d want near my morning coffee. The chemical comes with real health risks. If you’ve spent time in a lab, you know that even a quick dash of carelessness with chemicals can cause trouble. Gcle, like many other reagents, can irritate skin, damage lungs, and lead to severe problems if inhaled or swallowed. I’ve seen a colleague end up with a rash because she skipped gloves “just this once.” That made a lasting impression on me—and pushed our lab to review protocols.
No one should trust bare hands to keep chemical hazards at bay. Putting on proper gloves, usually nitrile, is simple and keeps skin from absorbing harmful substances. Some chemicals can eat right through latex or regular cleaning gloves, so picking the right material matters. I always check the safety datasheet in advance. Any direct contact becomes a gamble. Sometimes a spill means an uncomfortable few hours; some mistakes could mean hospital visits. Better to grab a new pair of gloves than call a doctor.
One splash near your eyes and that’s all it takes. Standard procedure in my experience calls for goggles or a face shield whenever working with volatile or splashing chemicals. I’ve watched people ignore their eye protection because "it only takes a second." One mishap can cause a trip to the emergency department and weeks of regret. Breathing in fumes isn’t always dramatic at first, but over time, even mild exposures add up. For volatile solvents or powders, a certified lab coat and a properly fitted mask should never gather dust on a hook—respirators with the right filters take things a step further when volatility or dust is an issue.
Spills cause chaos, even in well-run labs. If Gcle gets out, you don’t want everyone scrambling for answers. Spill kits need to be stocked and accessible. The best accident is the one that doesn’t happen, so work in a fume hood whenever possible, keeping the sash low for maximum protection. Simple habits, like tightly sealing containers, stopping to double-check labels, and never pipetting by mouth, can make a world of difference. I remember a time a misread label led to confusion over clean-up procedures—better labeling practices could have saved time and worry.
No one gets safety right by guessing. Up-to-date training helps prevent costly mistakes. Years ago, I saw a new technician try to neutralize a spill in the wrong way and make the situation worse. Regular refreshers and drills make a huge difference. Clear signage, step-by-step protocols, and a workplace culture where questions aren’t brushed aside all help form a safety net. Encouraging a team to speak up when things look off can spare everyone problems.
Throwing excess Gcle down the drain might feel quick, but local regulations say otherwise. Collecting chemical waste in labeled, compatible containers keeps substances from mixing and causing surprise reactions. Hazardous waste services exist for a reason, and the cost of a pickup beats the price of fines or bigger troubles with public health. If you’re not sure where to dispose of something, it’s better to pause and ask.
Most accidents happen when people try to save time or cut corners. Building daily routines around safety—clean workbench, PPE ready to grab, plans for spills—keeps risk low and confidence high. Seeing coworkers take care inspires everyone else to do the same. No one wants a story about a preventable accident to become the main topic on Monday morning.
| Names | |
| Preferred IUPAC name | (6R,7R)-7-(2-Phenylacetamido)-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-(methoxybenzyl) ester |
| Other names |
G-cle GCLE 7-PMA-3-CMA-4-CPA-p-methoxybenzyl ester |
| Pronunciation | /ˈdʒiː.siː.iːl ˈsɛv.ən ˌfɛn.ɪl.əkˈsɛt.əˌmɪd.oʊ ˈθriː ˌklɔːr.oʊˈmɛθ.ɪl ˈfɔːr ˌsɛf.ə.ləˈspɔːr.æn.ɪk əˈsɪd ˌpiː ˈmɛθ.ɒk.siˌbenz.il ˈɛstər/ |
| Identifiers | |
| CAS Number | 56187-47-4 |
| 3D model (JSmol) | `/5K-16)N2C(=O)[C@H](NC(=O)Cc1ccccc1)[C@@H]2SC1=C(Cl)C=CC(=O)C1[P](OCc1ccc(OC)cc1)=O` |
| Beilstein Reference | 2226076 |
| ChEBI | CHEBI:131754 |
| ChEMBL | CHEMBL2105932 |
| ChemSpider | 21545908 |
| DrugBank | DB21156 |
| ECHA InfoCard | 100.160.384 |
| Gmelin Reference | 1833495 |
| KEGG | C14147 |
| MeSH | D04.210.500.400.400.800 |
| PubChem CID | 123656 |
| RTECS number | DG8575000 |
| UNII | UU8K1O1ONZ |
| UN number | Not regulated |
| CompTox Dashboard (EPA) | DTXSID90846720 |
| Properties | |
| Chemical formula | C23H21ClN2O6S |
| Molar mass | 513.97 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | Density: 1.5±0.1 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.42 |
| Acidity (pKa) | 2.5 |
| Basicity (pKb) | 8.6 |
| Refractive index (nD) | 1.637 |
| Dipole moment | 7.03 D |
| Pharmacology | |
| ATC code | J01DB04 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| Lethal dose or concentration | LD50 oral rat > 5gm/kg |
| LD50 (median dose) | LD50 (median dose): Mouse (oral) LD50 > 5 g/kg |
| REL (Recommended) | 300 μg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Cephalexin Cephalothin Cefazolin Cephapirin Cephradine Cefadroxil |
